BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 29070111)

  • 21. [Anti-leukemia effect of oridonin on T-cell acute lymphoblastic leukemia].
    Guo Y; Shan QQ; Gong YP; Lin J; Yang X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Nov; 45(6):903-7. PubMed ID: 25571712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guggulsterone of Commiphora mukul resin reverses drug resistance in imatinib-resistant leukemic cells by inhibiting cyclooxygenase-2 and P-glycoprotein.
    Xu HB; Xu LZ; Mao XP; Fu J
    Phytomedicine; 2014 Jun; 21(7):1004-9. PubMed ID: 24680616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
    Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
    Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
    Yandim MK; Ceylan C; Elmas E; Baran Y
    Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cytotoxic activities of Celecoxib on leukemic cells and the synergistic effects of Celecoxib with Imatinib thereupon].
    Li RJ; Gong FJ; Zhang GS
    Zhonghua Yi Xue Za Zhi; 2006 May; 86(20):1417-20. PubMed ID: 16796927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oridonin-induced apoptosis in leukemia K562 cells and its mechanism.
    Liu JJ; Huang RW; Lin DJ; Wu XY; Peng J; Pan XL; Song YQ; Lin Q; Hou M; Wang DN; Chen F; Zhang MH
    Neoplasma; 2005; 52(3):225-30. PubMed ID: 15875084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effects of Quercetin on Chronic Myeloid Leukemia Cell Line Resistant to Imatinib and Its Mechanism].
    Lu HY; Chen J; DU SH; Jia PM; Tong JH; Wu YL; Zhou L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):346-352. PubMed ID: 28446273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of A Novel Emodin Derivative on Chronic Myelogenous Leukemia K562 Cells and Imatinib-resistant K562/G01 Cells].
    Li BJ; Liu TB; Wang WF; Lin MH; Hu JD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):1-7. PubMed ID: 26913384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments.
    Xu L; Zhao Y; Pan F; Zhu M; Yao L; Liu Y; Feng J; Xiong J; Chen X; Ren F; Tan Y; Wang H
    Biomed Res Int; 2019; 2019():6502793. PubMed ID: 31828114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
    Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
    Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of Homoharringtonine Combined with Imatinib on the K562/G01 Cells and Its Mechanism].
    Wu JJ; Ding YH; Deng ZK; Shi YY; Lu XY; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):80-84. PubMed ID: 28245379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
    Okabe S; Tauchi T; Ohyashiki K
    Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
    Tolomeo M; Grimaudo S; Di Cristina A; Pipitone RM; Dusonchet L; Meli M; Crosta L; Gebbia N; Invidiata FP; Titone L; Simoni D
    Cancer Lett; 2008 Jul; 265(2):289-97. PubMed ID: 18374481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.
    Ito T; Tanaka H; Kimura A
    Eur J Haematol; 2007 May; 78(5):417-31. PubMed ID: 17432977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of tanshinone II A on leukemia cell line K562].
    Shan QQ; Guo Y; Gong YP
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 May; 45(3):410-3. PubMed ID: 24941807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
    Farhadi E; Zaker F; Safa M; Rezvani MR
    Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
    Gamas P; Marchetti S; Puissant A; Grosso S; Jacquel A; Colosetti P; Pasquet JM; Mahon FX; Cassuto JP; Auberger P
    Leukemia; 2009 Aug; 23(8):1500-6. PubMed ID: 19340007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anti-leukemia effect of oridonin on Ph(+) acute lymphoblastic leukemia cell SUP-B15].
    Guo Y; Shan QQ; Gong YP; Lin J; Yang X; Zhou RQ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):439-43. PubMed ID: 22967375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.